Werewolf Therapeutics, Inc.
3 clinical trials · Sponsor
◉ Watch Werewolf Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma (NCT06939283) | Werewolf Therapeutics, Inc. | 2025-05-07 |
| WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (NCT05678998) | Werewolf Therapeutics, Inc. | 2022-12-06 |
| Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors (NCT05479812) | Werewolf Therapeutics, Inc. | 2022-05-20 |
Track Werewolf Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.